Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts

BACKGROUND: The success of agents that reverse T-cell inhibitory signals, such as anti-PD-1/PD-L1 therapies, has reinvigorated cancer immunotherapy research. However, since only a minority of patients respond to single-agent therapies, methods to test the potential anti-tumor activity of rational co...

Descripción completa

Detalles Bibliográficos
Autores principales: Capasso, A., Lang, J., Pitts, T. M., Jordan, K. R., Lieu, C. H., Davis, S. L., Diamond, J. R., Kopetz, S., Barbee, J., Peterson, J., Freed, B. M., Yacob, B. W., Bagby, S. M., Messersmith, W. A., Slansky, J. E., Pelanda, R., Eckhardt, S. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368764/
https://www.ncbi.nlm.nih.gov/pubmed/30736857
http://dx.doi.org/10.1186/s40425-019-0518-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368764/
https://www.ncbi.nlm.nih.gov/pubmed/30736857
http://dx.doi.org/10.1186/s40425-019-0518-z

Ejemplares similares